Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-glucuronidase-mediated drug release.

Michelle de Graaf1, Epie Boven, Hans W Scheeren

  • 1Department of Medical Oncology, Division of Gene Therapy, Vrije Universiteit Medical Centre, P.O. Box 7057, Amsterdam, 1007 MB, The Netherlands.

Current Pharmaceutical Design
|June 8, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Journal for immunotherapy of cancer·2026
Same author

Small Molecule MIF Modulation Enhances Ferroptosis by Impairing DNA Repair Mechanisms.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2024
Same author

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

The Journal of experimental medicine·2023
Same author

Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

JAMA oncology·2023
Same author

An Automated, Open-Source Workflow for the Generation of (3D) Fragment Libraries.

ACS medicinal chemistry letters·2023
Same author

Ultrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives.

Theranostics·2022

Cancer prodrugs activated by beta-glucuronidase offer targeted therapy. New prodrugs with slower clearance and enhanced enzyme targeting show promise for improved anti-tumour effects and reduced toxicity.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Selective drug activation at the tumor site can improve efficacy and reduce toxicity.
  • Beta-glucuronidase is an enzyme found in tumor necrotic areas, making it a target for prodrug activation.
  • Current glucuronide prodrugs face challenges with rapid renal clearance.

Purpose of the Study:

  • To explore the potential of beta-glucuronidase-activated prodrugs for cancer therapy.
  • To address the limitations of current glucuronide prodrugs, such as fast renal clearance.
  • To investigate strategies for enhancing tumor-specific enzyme levels and prodrug efficacy.

Main Methods:

  • Synthesis of glucuronide prodrugs designed for beta-glucuronidase activation.
  • Development of antibody-directed enzyme prodrug therapy (ADEPT) and gene-directed enzyme prodrug therapy (GDEPT) approaches.

Related Experiment Videos

  • Evaluation of anthracyclin-based glucuronide prodrugs and their therapeutic effects.

    • Main Results:

    • Glucuronide prodrugs are relatively non-toxic and can be activated by beta-glucuronidase.
    • Anthracyclin-based glucuronide prodrugs demonstrated favorable therapeutic effects compared to parent drugs.
    • ADEPT and GDEPT strategies combined with glucuronide prodrugs showed enhanced efficacy in experimental tumor models.

    Conclusions:

    • Glucuronide prodrugs hold significant promise as a monotherapy for cancer treatment.
    • Further development of less hydrophilic prodrugs is needed to improve pharmacokinetic profiles.
    • Targeting beta-glucuronidase to the tumor site can enhance therapeutic effects, potentially benefiting patients with small lesions.